Fagron NV (FAGR) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.167x

Based on the latest financial reports, Fagron NV (FAGR) has a cash flow conversion efficiency ratio of 0.167x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€93.07 Million ≈ $108.81 Million USD) by net assets (€556.26 Million ≈ $650.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Fagron NV to measure how many days the company can operate on defensive assets alone.

Fagron NV - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Fagron NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Fagron NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fagron NV ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
BIEM.L .FDLKK Garment Co Ltd
SHE:002832
0.029x
Megaport Ltd
AU:MP1
0.069x
Hugel Inc
KQ:145020
0.056x
Dalian Zeus Entertainment
SHE:002354
-0.005x
4iG Nyrt.
BUD:4IG
0.147x
Xi'an Sinofuse Electric Co. Ltd.
SHE:301031
N/A
Cimpress plc
F:3UF
0.036x
CBIZ Inc
NYSE:CBZ
-0.013x

Annual Cash Flow Conversion Efficiency for Fagron NV (2004–2025)

The table below shows the annual cash flow conversion efficiency of Fagron NV from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Fagron NV.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €556.26 Million
≈ $650.32 Million
€128.28 Million
≈ $149.97 Million
0.231x +6.05%
2024-12-31 €505.36 Million
≈ $590.82 Million
€109.89 Million
≈ $128.48 Million
0.217x -5.30%
2023-12-31 €467.63 Million
≈ $546.70 Million
€107.38 Million
≈ $125.54 Million
0.230x -14.28%
2022-12-31 €408.63 Million
≈ $477.73 Million
€109.46 Million
≈ $127.97 Million
0.268x +11.17%
2021-12-31 €325.47 Million
≈ $380.50 Million
€78.42 Million
≈ $91.68 Million
0.241x -33.17%
2020-12-31 €257.82 Million
≈ $301.42 Million
€92.95 Million
≈ $108.67 Million
0.361x +15.13%
2019-12-31 €246.44 Million
≈ $288.12 Million
€77.17 Million
≈ $90.23 Million
0.313x -10.38%
2018-12-31 €209.72 Million
≈ $245.18 Million
€73.28 Million
≈ $85.67 Million
0.349x -23.32%
2017-12-31 €184.88 Million
≈ $216.15 Million
€84.25 Million
≈ $98.49 Million
0.456x +3.20%
2016-12-31 €152.87 Million
≈ $178.73 Million
€67.50 Million
≈ $78.92 Million
0.442x +139.01%
2015-12-31 €-64.77 Million
≈ $-75.73 Million
€73.31 Million
≈ $85.71 Million
-1.132x -274.67%
2014-12-31 €156.94 Million
≈ $183.48 Million
€101.70 Million
≈ $118.89 Million
0.648x +59.40%
2013-12-31 €155.17 Million
≈ $181.41 Million
€63.08 Million
≈ $73.74 Million
0.407x +47.25%
2012-12-31 €245.38 Million
≈ $286.88 Million
€67.74 Million
≈ $79.20 Million
0.276x -15.64%
2011-12-31 €220.45 Million
≈ $257.73 Million
€72.15 Million
≈ $84.35 Million
0.327x +61.69%
2010-12-31 €208.12 Million
≈ $243.32 Million
€42.13 Million
≈ $49.25 Million
0.202x +0.63%
2009-12-31 €196.35 Million
≈ $229.56 Million
€39.50 Million
≈ $46.17 Million
0.201x +34.53%
2008-12-31 €185.53 Million
≈ $216.90 Million
€27.74 Million
≈ $32.43 Million
0.150x -1.67%
2007-12-31 €178.22 Million
≈ $208.36 Million
€27.10 Million
≈ $31.68 Million
0.152x -17.89%
2006-12-31 €94.88 Million
≈ $110.93 Million
€17.57 Million
≈ $20.54 Million
0.185x -55.57%
2005-12-31 €82.87 Million
≈ $96.88 Million
€34.54 Million
≈ $40.38 Million
0.417x +372.91%
2004-12-31 €102.54 Million
≈ $119.88 Million
€9.04 Million
≈ $10.57 Million
0.088x --

About Fagron NV

BR:FAGR Belgium Drug Manufacturers - Specialty & Generic
Market Cap
$2.09 Billion
€1.79 Billion EUR
Market Cap Rank
#6636 Global
#33 in Belgium
Share Price
€24.35
Change (1 day)
-1.62%
52-Week Range
€19.58 - €25.25
All Time High
€25.25
About

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more